Acurx Pharmaceuticals Inc Stock Price, News & Analysis

Acurx Pharmaceuticals (NASDAQ: ACXP) reported its Q1 2025 financial results and business updates. The company raised $3.6 million through two registered direct offerings and secured a $12 million equity line of credit. Q1 financial highlights include a net loss of $2.1 million ($0.11 per share), improved from a $4.4 million loss year-over-year, with reduced R&D expenses of $0.6 million and G&A expenses of $1.6 million.

Key developments include positive EMA guidance for ibezapolstat's Phase 3 clinical trial program, aligned with FDA requirements. Two significant studies funded by NIAID demonstrated ibezapolstat's microbiome-restorative potential and favorable gut microbiome impact compared to other antibiotics. The company also secured new patents in Japan and India for DNA polymerase IIIC inhibitors, extending protection until December 2039.

Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, has scheduled its first quarter 2025 financial results conference call for May 13, 2025, at 8:00 am ET.

The conference call will be led by David P. Luci, President and CEO, and Robert G. Shawah, Chief Financial Officer. They will present the financial results and provide a business update before the U.S. markets open.

Interested participants can join the call using the following details:

• U.S. Toll-free: 1-877-790-1503
• Conference ID: 13753625
• International callers can access toll-free numbers via a dedicated website

Acurx Pharmaceuticals (Nasdaq: ACXP) has announced its participation in the Alliance Global Partners (A.G.P) Healthcare Company Showcase on May 21, 2025, at 9:00 a.m. ET. David P. Luci, President & CEO, will engage in a virtual fireside chat presentation.

The company, which specializes in developing small molecule antibiotics for difficult-to-treat bacterial infections, will showcase its lead antibiotic candidate ibezapolstat (IBZ). This drug is prepared to progress to international Phase 3 clinical trials for treating C. difficile infection (CDI).

The presentation will be available via live webcast, with a replay accessible through the News/Events section on the company's website at www.acurxpharma.com.

Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the Indian Patent Office in March 2025 for DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This adds to their existing portfolio of three U.S. patents, one Israeli patent, and one Japanese patent, all covering the ACX-375C program.

The company's lead DNA pol IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile Infection. Their second-generation compounds are being developed for both oral and parenteral use to treat infections caused by gram-positive bacteria, including:

• Staphylococcus aureus (including MRSA)
• VRE and DRSP
• B. anthracis (anthrax), a Bioterrorism Category A Threat-Level pathogen

Acurx Pharmaceuticals (NASDAQ: ACXP) has reported its Q4 and full-year 2024 results. Key highlights include positive Phase 2b clinical trial results for ibezapolstat, showing a 96% clinical cure rate across combined Phase 2 trials, with 100% sustained cure rate through one month post-treatment, compared to 86% for vancomycin.

The company secured positive regulatory guidance from EMA for ibezapolstat's Phase 3 program, aligning with FDA requirements. Financial results show cash position of $3.7 million as of December 31, 2024, down from $7.5 million year-over-year. The company raised $6.6 million through ATM financing in 2024.

Q4 2024 showed reduced losses with net loss of $2.8 million ($0.16 per share) compared to $5.1 million ($0.37 per share) in Q4 2023. Full-year 2024 net loss was $14.1 million ($0.87 per share) versus $14.6 million ($1.15 per share) in 2023.

Acurx Pharmaceuticals (NASDAQ: ACXP) has announced the closing of a $1.1 million registered direct offering, consisting of 2,745,000 shares of common stock priced at $0.40 per share. The late-stage biopharmaceutical company, focused on developing new antibiotics for difficult-to-treat bacterial infections, also issued unregistered warrants in a concurrent private placement.

The warrants allow for the purchase of up to 8,235,000 shares at an exercise price of $0.40 per share, exercisable upon stockholder approval and expiring 24 months thereafter. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.

Acurx Pharmaceuticals (NASDAQ: ACXP) has announced a $1.1 million registered direct offering of 2,745,000 shares of common stock at $0.40 per share. The late-stage biopharmaceutical company, focused on developing new antibiotics for difficult-to-treat bacterial infections, will also issue unregistered warrants for up to 8,235,000 shares in a concurrent private placement.

The warrants will have an exercise price of $0.40 per share and will expire 24 months after stockholder approval. The offering, expected to close around March 10, 2025, is being managed by H.C. Wainwright & Co. as the exclusive placement agent.

The company plans to use the net proceeds for working capital and general corporate purposes. The common stock shares are being offered through a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.

Acurx Pharmaceuticals (NASDAQ: ACXP) has published groundbreaking research comparing the gut microbiome effects of its lead antibiotic candidate ibezapolstat (IBZ) with other antibiotics used to treat C. difficile Infection (CDI).

The study, published in the Journal of Antimicrobial Agents and Chemotherapeutics, revealed that IBZ caused less disruption to gut microbiome diversity compared to vancomycin (VAN) and metronidazole (MET). The research showed IBZ increased the relative abundance of Bacteroidota and Actinomycetota phyla, with the latter including beneficial bacteria like Bifidobacteria.

Notable differences were observed between IBZ and fidaxomicin (FDX), potentially differentiating these two anti-CDI antibiotics in future studies. IBZ is preparing to advance to international Phase 3 clinical trials for CDI treatment and has received FDA QIDP, Fast-Track Designation, and EMA SME designation.

Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, has scheduled its fourth quarter and full year 2024 financial results conference call for March 18, 2025, at 8:00 am ET. The announcement will take place before U.S. market opening, with President and CEO David P. Luci and CFO Robert G. Shawah hosting the call to discuss financial performance and provide a business update.